A security framework for mobile communication

The security vulnerabilities in current GSM networks allow eavesdroppers to monitor entire communication between the mobile device and the base station over the air. In this thesis, a security framework for mobile communication is proposed. Within this framework, we develop a secure key exchange protocol using Elliptic Curve Diffie Hellman (ECDH). We further employ double hash chains for session key generation in order not to repeat resource-hungry ECDH operations too often and in order to provide forward and backward secrecy. We adopt this key exchange and generation protocol to short message service (SMS) and voice communication in mobile environment. As a proof of concept, we also implement our framework on Android platform. Moreover, we analyzed the performance of our framework using different mobile equipments. For the voice communication protocol, we also measure the data network performance for various places in the city

Transducer Technologies for Biosensors and Their Wearable Applications

The development of new biosensor technologies and their active use as wearable devices have offered mobility and flexibility to conventional western medicine and personal fitness tracking. In the development of biosensors, transducers stand out as the main elements converting the signals sourced from a biological event into a detectable output. Combined with the suitable bio-receptors and the miniaturization of readout electronics, the functionality and design of the transducers play a key role in the construction of wearable devices for personal health control. Ever-growing research and industrial interest in new transducer technologies for point-of-care (POC) and wearable bio-detection have gained tremendous acceleration by the pandemic-induced digital health transformation. In this article, we provide a comprehensive review of transducers for biosensors and their wearable applications that empower users for the active tracking of biomarkers and personal health parameters

TIP FAKÜLTESİ DÖNEM 1 VE DÖNEM 6 ÖĞRENCİLERİNDE AŞIRI AKTİF MESANE PREVALANSI

Amaç: Tıp fakültesi 1. Sınıf ve 6. Sınıf öğrencilerinde AAM sorgulama formukullanarak AAM prevalansını hesaplamak ve akran eğitiminin etkinliğinideğerlendirmek amaçlandı. Gereç veyöntemler: Katılımcılardanbilgilendirilmiş onam formu alındıktan sonra aşırı aktif mesane değerlendirmeformu (veri kayıt formu) ile prevalans hesaplanması yapılacaktırBulgular: Çalışmamıza 307gönüllü katıldı. Gönüllülerin 183’ü (%59,6) erkek 124’ü (%40,4) kadındı. 307gönüllünün 128’inin (%41.7) aşırı aktif mesane sorgulama formunda 8’in üzerindesemptom skoru olduğu gözlendi (Tablo 1). 128 gönüllüden 11’inde, semptom skoru8’in altında olan 179 gönüllüden 14’ünde öksürme veya gülme ile idrar kaçırmaolduğu tespit edildi. 128 gönüllüden 20’si (%15,6) tedavi almışken 108’inin(%84,4) mevcut aşırı aktif mesane semptomları için doktor başvurusubulunmamaktaydı. Aşırı aktif mesane tanısı ile tedavi alan 20 gönülünün16’sının (%80) tedaviden fayda gördüğü, 4’ünün tedaviden fayda görmediği tespitedildi (Tablo 2).Sonuç: Aşırı aktifmesane hastalığı prevelansının tanımlanan toplulukta %41 gibi yüksek bir değeresahip olduğu tespit edildi. Bu hastalığın %84’nün tanısız tedavisiz kaldığıgörülmüştür. Uygun tedavi ile %80 gibi yüksek bir oranda tedaviden faydagörüldüğü ortaya konmuştur.Tablo 1: Katılımcıların AAM skoruna göre dağılımı Katılımcı sayısı: 307 AAM skoru&lt;8 AAM skoru&gt;8 Erkek 183 88 95 Kadın 124 91 33 İnkontinans var 14 11 İnkontinans yok 165 117 &nbsp;Tablo2: Tedavi alma ve doktora başvurma öyküsü Tedavi alan Tedavi Almayan 20 108 Tedaviden fayda gören Tedaviden fayda görmeyen Tedavi almama sebebi 16 4 Hastalık olarak değerlendirmeme 62 Gelip geçici olduğunu düşünme 22 Semptomların çok rahatsız etmemesi 18 Doktora gitmede çekince 6 &nbsp;</p

XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer

Background/Aims: The efficacy and tolerability of oxaliplatin in combination with either folinic acid, fluorouracil (5-FU) (FOLFOX4 regimen) or capecitabine (XELOX regimen) was evaluated in advanced pancreatic cancer. Methodology: In this study, eighty-five patients with advanced pancreatic cancer were enrolled after failing to gemcitabine-based chemotherapy between November 2005 and August 2011. FOLFOX4 was repeated every two weeks and XELOX regimen was repeated every three weeks until either disease progression or unacceptable toxicity occurred. Results: Eighty-five patients were evaluated for tumor response. Seven patients (18%) achieved a partial response with XELOX and stable disease was observed in 16 patients (41%). Eight patients (17%) achieved a partial response with FOLFOX4 and stable disease was observed in 12 patients (26%). Disease control rates were 59% in the XELOX arm and 43% in the FOLFOX4 arm. The median time to progression was 16 weeks in both arms. The median overall survival was 21 weeks with XELOX and 25 weeks with FOLFOX4. Conclusions: Oxaliplatin-based combination therapy showed moderate clinical activity with acceptable toxicity in patients who had progressive disease after receiving gemcitabine-based chemotherapy for advanced and/or metastatic pancreatic cancer. We conclude that XELOX is similar in terms of efficacy and toxicity profile to FOLFOX4 in the second-line treatment of metastatic pancreatic cancer

Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.

We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC)

Advisory Board of This Issue

Relation of diabetes to coronary artery ectasia: A meta-analysis Qiao-Juan Huang et al.; Beijing, Guangxi-China Original Investigations Hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats Yasemin Benderli Cihan et al.; Kayseri-Turkey Editorial Comment: The impact of radiotherapy, trastuzumab and hormonal therapy on cardiac fibrosis Alberto Farolfi; Meldola-Italy The relationship between coronary collateral artery development and inflammatory markers Didem Oğuz et al.; İstanbul-Turkey Interrelation of RDW and coronary flow reserve in patient with idiopathic dilated cardiomyopathy Mehmet Özülkü et al.; Konya-Turkey Editorial Comment: RDW and low coronary flow reserve in patients with dilated cardiomyopathy Yuji Nishizaki et al.; Tokyo-Japan Heart rate recovery may predict the presence of coronary artery disease Aydın Akyüz et al.; Tekirdağ-Turkey Homocysteine levels in patient with masked hypertension Kamile Yücel et al.; Konya-Turkey Effect of antihypertensive treatment on endothelial markers in hypertension: A randomized study Mehmet Ali Nahit Şendur et al.; Ankara-Turkey Right ventricule, exercise capacity and quality of life: associations with NT-proBNP in COPD Tuğce Şahin Özdemirel et al.; Ankara-Turkey Breast arterial calcifications, carotid intima-media thickness and hemodynamics Ramazan Büyükkaya et al.; Düzce-Turkey Aerosolized iloprost and oxygen: pulmonary vasoreactivity in children with pulmonary hypertension Özlem Elkıran et al.; Malatya-Turkey Review How to estimate left ventricular hypertrophy in hypertensive patients Dragan Lovic et al.; Nis-Serbi

The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study

Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of &#8805;60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment.nMedian overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (&#8805;5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA